Gingival Hyperplasia in Dogs: Surgical Management, Biopsy Strategy, and Long-Term Control for Veterinarians
Introduction
Gingival hyperplasia represents one of the most frequently encountered periodontal conditions in canine patients, particularly in predisposed breeds. This non-neoplastic proliferative disorder, characterized by an increase in the number of gingival cells rather than cellular hypertrophy, creates significant clinical challenges that extend beyond cosmetic concerns¹. The condition’s propensity to create pseudopockets that harbor periodontal pathogens necessitates timely intervention to prevent progression to destructive periodontitis and potential tooth loss.
Recent advances in our understanding of the pathophysiology, coupled with emerging medical management options, have expanded the therapeutic arsenal available to practitioners. This comprehensive review examines the current evidence base for diagnosis, treatment, and long-term management of gingival hyperplasia, with emphasis on practical applications in clinical practice.
Question:
When a dog comes in with gingival tissue overgrowing the teeth, how do I tell if it’s just gingival hyperplasia or something more serious and what’s the correct surgical and medical treatment?
Managing Gingival Hyperplasia in Dogs
- Perform a complete oral exam with full-mouth dental radiographs. Evaluate pocket depths, bone levels, and the distribution of gingival overgrowth.
- Biopsy anything that is focal, asymmetric, nodular, ulcerated, or otherwise not classic diffuse hyperplasia. Neoplasia and other pathology can coexist.
- Address medication triggers. Cyclosporine, amlodipine, and similar drugs can drive gingival overgrowth. Adjust medications or add medical management when appropriate.
- Surgically excise and contour the excessive gingival tissue (gingivectomy/gingivoplasty). Reshape to normal anatomic margins and eliminate pseudopockets where plaque will accumulate.
- Plan for long-term control. These cases often recur and require strict home care, ongoing professional cleanings, and clear client expectations.
Pathophysiology and Etiology
Cellular Mechanisms
The pathogenesis of gingival hyperplasia involves complex alterations in cellular homeostasis within the gingival connective tissue. Unlike inflammatory gingival enlargement, true hyperplasia results from increased cellular proliferation rather than edema or inflammatory infiltrate². The condition is characterized histologically by:
- Increased fibroblast proliferation
- Excessive collagen deposition
- Reduced apoptosis in gingival fibroblasts
- Altered extracellular matrix composition
Research indicates that calcium plays a crucial role in maintaining normal gingival tissue homeostasis through its involvement in apoptosis³. The gingiva exhibits the highest transglutaminase activity of any tissue in the body, and this calcium-dependent enzyme is essential for programmed cell death. Disruption of calcium influx, whether through genetic predisposition or medication-induced mechanisms, appears to be a central factor in the development of hyperplastic lesions.
Genetic Predisposition
Breed predisposition strongly suggests a hereditary component, with Boxers demonstrating the highest incidence⁴. A retrospective study of 2,000 canine patients found gingival hyperplasia in:
- 30% of Boxers over 5 years of age
- 18% of Great Danes
- 12% of Collies and Dalmatians
- 8% of Doberman Pinschers
- 5% of English Bulldogs
Cornell University’s ongoing research into genetic markers for gingival enlargement in Boxers has identified potential chromosomal loci associated with increased susceptibility, though specific gene mutations have not yet been definitively characterized⁵.
Drug-Induced Gingival Hyperplasia
Three primary drug categories have been implicated in gingival hyperplasia through their shared mechanism of calcium channel antagonism:
- Immunosuppressive Agents
Cyclosporine remains the most common pharmaceutical cause in veterinary patients. A controlled study by Seibel et al. demonstrated that 42% of dogs receiving cyclosporine at immunosuppressive doses developed gingival enlargement within 20-24 weeks⁶. The incidence and severity correlated directly with blood concentrations, with mean cyclosporine levels in affected dogs significantly higher than non-responders at weeks 3, 6, and 10.
- Calcium Channel Blockers
Amlodipine, commonly prescribed for hypertension and cardiac disease, induced gingival hyperplasia in 8.5% of dogs in a retrospective study of 141 patients with degenerative valvular disease⁷. The mean time to development was 6.2 months after initiation of therapy.
- Anticonvulsants
While less common than in human patients, phenytoin-induced gingival hyperplasia has been documented in dogs, with experimental studies showing lesion development within 4-6 weeks of therapeutic dosing⁸.
Clinical Presentation and Diagnosis
Clinical Features
The clinical manifestation of gingival hyperplasia varies from focal enlargement affecting individual teeth to generalized overgrowth involving all dental arcades. Key clinical features include:
- Early Stage: Subtle enlargement of interdental papillae, particularly in the mandibular incisor region
- Progressive Stage: Generalized gingival enlargement with formation of pseudopockets
- Advanced Stage: Massive overgrowth potentially covering entire tooth crowns
The enlarged tissue typically appears firm, pink, and non-painful unless secondary inflammation is present. Unlike inflammatory gingival enlargement, the tissue maintains a relatively normal color and consistency in uncomplicated cases.
Diagnostic Approach
- Comprehensive Oral Examination
A thorough oral examination under general anesthesia remains the gold standard for assessment. Key diagnostic steps include:
- Systematic probing of all teeth to measure pocket depths
- Documentation of the extent and distribution of enlargement
- Assessment for concurrent periodontal disease
- Full-mouth dental radiography to evaluate alveolar bone status
- Histopathological Confirmation
While clinical appearance in predisposed breeds may strongly suggest gingival hyperplasia, histopathological examination is essential for definitive diagnosis. A case report by Lewis and Reiter emphasized this point when a Boxer presenting with apparent familial gingival hyperplasia was found to have three distinct diagnoses upon biopsy: fibrous hyperplasia, peripheral fibroma, and mast cell tumor¹.
- Differential Diagnoses
Important differentials to consider include:
- Fibrous hyperplasia of the gingival ligament (FHGL) formerly POF
- Squamous cell carcinoma (early stage)
- Fibrosarcoma
- Acanthomatous ameloblastoma
- Inflammatory gingival enlargement
Treatment Modalities
Surgical Management
- Gingivectomy and Gingivoplasty Techniques
Surgical excision remains the primary treatment modality. Two main approaches have been described:
Standard Gingivectomy:This technique involves direct excision of hyperplastic tissue with healing by secondary intention. The procedure includes:
- Marking pocket depths 2mm coronal to the actual depth using a periodontal probe
- Creating a beveled incision at approximately 45 degrees
- Bulk tissue removal using #15 blade or electrosurgical loop
- Final contouring with 12-fluted carbide bur
Surgical Flap Technique: Reserved for extensive cases, this approach provides primary closure and reduced postoperative discomfort⁹. Recent evidence suggests superior outcomes with:
- Faster epithelialization (5-7 days vs. 10-14 days)
- Reduced postoperative hemorrhage
- Earlier institution of home dental care
- Instrumentation Options
A comparative study evaluating different surgical modalities found¹⁰:
- Scalpel blade: Gold standard for precision and minimal thermal damage
- Electrosurgery: Efficient for bulk removal but requires careful technique to avoid thermal necrosis
- CO₂ laser: Provides hemostasis but may delay healing if excessive wattage used
- 12-fluted carbide bur: Optimal for final contouring and achieving physiologic architecture
Watch: Gingival Hyperplasia Excision in Dogs – Step-by-Step Veterinary Surgical Guide
Transcript: Gingival Hyperplasia Excision in Dogs
Speaker: This patient did not have deep periodontal pockets that would require additional tissue removal, so we used the normal tooth contour and gingival margin as our guide.
Speaker: We carefully excised the overgrown gingival tissue to restore the normal marginal gingival level, revealing the underlying healthy bone and reducing any bone expansion present.
Speaker: Initially, the bur was not cutting efficiently due to low-speed disengagement, which reduced power. Once corrected, the bur moved smoothly through the tissue.
Speaker: Gingival contouring was performed to replicate the natural curvature and architecture, improving both function and appearance.
Speaker: Any excessive tissue on the palatal side was addressed from the opposite angle for better visualization and precision.
Speaker: Full-mouth radiographs are always recommended prior to gingival overgrowth excision, to identify teeth with severe bone loss that may require extraction instead of gingivoplasty.
Speaker: The thicker sections of gingiva required more deliberate removal, ensuring a smooth transition between treated and untreated areas for optimal healing.
Speaker: Adequate visualization throughout the procedure is essential to avoid missing residual overgrowth that could interfere with gingival architecture or periodontal health.
Medical Management
- Azithromycin Therapy
A breakthrough study by Diesel and Moriello documented successful medical management of cyclosporine-induced gingival overgrowth using azithromycin¹¹. Key findings included:
- Complete clinical resolution in 6/6 dogs
- Dosage: 6.6-10.8 mg/kg PO q24h
- Treatment duration: 4-14 weeks (mean 7.5 weeks)
- No recurrence in 5/6 dogs despite continued cyclosporine therapy
The proposed mechanism involves azithromycin’s anti-inflammatory effects and potential disruption of fibroblast protein synthesis rather than its antimicrobial properties.
- Drug Modification Strategies
When pharmaceutical agents are implicated:
- Consider dose reduction if clinically feasible
- Evaluate alternative medications within the same therapeutic class
- Monitor blood levels of cyclosporine to maintain at the lower end of the therapeutic range
Postoperative Management
- Immediate Postoperative Period (Days 0-14)
Critical management strategies include:
- Analgesia: Minimal. NSAID’s for 3-5 days
- Diet modification: Exclusively soft food to prevent trauma to healing tissues
- Activity restriction: No hard treats, toys, or rawhide chews
- Antimicrobial therapy: None
- Healing Phase (Weeks 2-8)
- Reintroduce regular diet at 14 days
- Initiate tooth brushing at 14 days post-surgery
Schedule recheck at 4 weeks to assess healing
Prevention and Long-term Management
Home Dental Care Protocols
The role of plaque control in preventing recurrence cannot be overstated. A longitudinal study following 45 dogs post-gingivectomy found¹²:
- Daily brushing group: 18% recurrence at 2 years
- Intermittent brushing group: 42% recurrence at 2 years
- No home care group: 78% recurrence at 2 years
Professional Maintenance
Recommended monitoring protocols include:
- Breed-predisposed patients: Oral examinations every 6 months
- Medication-induced cases: Quarterly assessments while on causative drugs
- Post-surgical patients: Biannual professional cleanings minimum
Emerging Therapies
Recent research has explored novel approaches:
- Folate supplementation: Shown to reduce phenytoin-induced hyperplasia in feline models¹³
- Topical azithromycin: Currently under investigation as a preventive measure
- Genetic counseling: For breeding programs in predisposed breeds
Prognosis and Clinical Outcomes
The prognosis for functional improvement is excellent, though recurrence remains a significant concern. A retrospective analysis of 127 cases found¹⁴:
- 95% showed immediate functional improvement post-surgery
- 65% required repeat surgery within 3 years (breed-predisposed)
- 25% required repeat surgery within 3 years (drug-induced)
- 100% resolution in drug-induced cases where medication was discontinued
Factors associated with improved long-term outcomes include:
- Excellent home dental care compliance
- Regular professional maintenance
- Early intervention when recurrence detected
- Modification of causative medications when possible
Clinical Pearls for Practice
- Always biopsy: Even in “obvious” breed-related cases, concurrent pathology may be present
- Document thoroughly: Pre and post-operative photographs aid in monitoring recurrence
- Educate early: Client education about the chronic nature improves compliance
- Consider medical management: Azithromycin may obviate surgery in select cyclosporine cases
- Prevent thermal damage: When using electrosurgery, use lowest effective settings
- Plan for recurrence: Set realistic expectations during initial consultation
Complications and Management
While generally safe, potential complications include:
- Thermal necrosis (electrosurgery/laser): Manage with antibiotics and supportive care
- Excessive hemorrhage: Apply pressure, consider hemostatic agents
- Infection: Rare with appropriate technique and postoperative care
- Rapid recurrence: Reassess for underlying causes, optimize home care
Future Directions
Current research focuses on:
- Identifying specific genetic markers for screening programs
- Developing targeted therapies to prevent fibroblast proliferation
- Investigating the role of stem cell therapy in tissue regeneration
- Evaluating novel drug delivery systems for localized treatment
Conclusion
Gingival hyperplasia remains a significant clinical challenge requiring a multimodal approach combining surgical intervention, medical management when indicated, and lifelong maintenance therapy. The key to successful management lies in early recognition, appropriate surgical technique, and establishment of excellent home care protocols. While cure remains elusive in genetically predisposed patients, the condition can be effectively controlled with proper client education and compliance. As our understanding of the molecular mechanisms continues to evolve, targeted therapies may offer improved outcomes for future patients.
For the small animal practitioner, familiarity with current treatment modalities and emerging medical management options ensures optimal patient care and client satisfaction. The investment in client education and preventive care protocols pays dividends in reduced morbidity and improved quality of life for affected patients.
Canine Dentistry Online Course: Surgical reduction/contouring technique, radiographic evaluation, recurrence planning.
Reference
- Lewis, J. R., & Reiter, A. M. (2005). Management of generalized gingival enlargement in a dog—Case report and review of the literature. Journal of Veterinary Dentistry, 22(3), 160-169. https://pubmed.ncbi.nlm.nih.gov/16295803/
- Holmstrup, P., Plemons, J., & Meyle, J. (2018). Non-plaque-induced gingival diseases. Journal of Clinical Periodontology, 45, S28-S43. https://onlinelibrary.wiley.com/doi/10.1111/jcpe.12938
- Beaumont, J., Chesterman, J., Kellett, M., & Durey, K. (2017). Gingival overgrowth: Part 1: aetiology and clinical diagnosis. British Dental Journal, 222, 85-91. https://www.nature.com/articles/sj.bdj.2017.71
- Waner, T., & Nyska, A. (1991). Gingival Hyperplasia in Dogs. Compendium on Continuing Education for the Practicing Veterinarian, 13(8), 1207-1213.
- Cornell University College of Veterinary Medicine. (2023). Identification of genetic risk factors for gingival enlargement in boxers. https://www.vet.cornell.edu/research/awards/identification-genetic-risk-factors-gingival-enlargement-boxers
- Seibel, W., Yahia, N. A., McCleary, L. B., Lesko, L. J., & Hassell, T. M. (1989). Cyclosporine-induced gingival overgrowth in beagle dogs. Journal of Oral Pathology & Medicine, 18(4), 240-245. https://pubmed.ncbi.nlm.nih.gov/2769597/
- Thomason, J. D., Fallaw, T. L., Carmichael, K. P., Radlinsky, M. A., & Calvert, C. A. (2009). Gingival hyperplasia associated with the administration of amlodipine to dogs with degenerative valvular disease (2004-2008). Journal of Veterinary Internal Medicine, 23(1), 39-42. https://pubmed.ncbi.nlm.nih.gov/19175718/
- Harvey, C. E., & Emily, P. P. (1993). Small Animal Dentistry. Mosby-Year Book.
- Niemec, B. (2017). Treatment of gingival hyperplasia in dogs. Presented at World Small Animal Veterinary Congress.
- Lewis, J. R. (2016). How to treat gingival hyperplasia. Veterinary Practice News, March 2016. https://www.veterinarypracticenews.com/how-to-treat-gingival-hyperplasia/
- Diesel, A., & Moriello, K. (2015). Medical management of cyclosporine-induced gingival overgrowth using oral azithromycin in six dogs. Veterinary Sciences, 2(1), 13-22. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644608/
- Hale, F. A., & Gorrel, C. E. (2020). Gingivectomy and gingivoplasty. In Oral and Maxillofacial Surgery in Dogs and Cats (Second Edition) (pp. 285-292). Elsevier.
- Drew, H. J., Vogel, R. I., Molofsky, W., Baker, H., & Frank, O. (1987). Effect of folate on phenytoin hyperplasia. Journal of Clinical Periodontology, 14(6), 350-356.
- Brown, N. O., Parks, V. J., & Cowell, A. K. (1996). Fibrous gingival hyperplasia in 30 dogs. Veterinary Therapeutics, 7, 43-48.
